Obsidian Therapeutics (OBX) – What Are Researchers Thinking About This Stock?

Obsidian Therapeutics (NASDAQ:OBX) has earned a consensus rating of “Moderate Buy” from the seven brokerages that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, four have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $39.00.

OBX has been the topic of a number of research reports. Leerink Partners assumed coverage on shares of Obsidian Therapeutics in a research note on Tuesday, September 22nd. They issued an “outperform” rating and a $32.00 target price on the stock. Piper Sandler started coverage on Obsidian Therapeutics in a research report on Wednesday, August 5th. They issued an “overweight” rating and a $42.00 price target for the company. Lifesci Capital assumed coverage on Obsidian Therapeutics in a research report on Tuesday, August 18th. They issued an “outperform” rating and a $43.00 price target for the company. Wall Street Zen raised Obsidian Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, September 27th. Finally, Zacks Research upgraded Obsidian Therapeutics to a “hold” rating in a research report on Thursday, August 6th.

Obsidian Therapeutics Price Performance

Shares of NASDAQ OBX opened at $13.00 on Friday. Obsidian Therapeutics has a 12-month low of $12.07 and a 12-month high of $49.97. The company’s 50-day simple moving average is $18.25.

About Obsidian Therapeutics

Obsidian Therapeutics is a biotechnology company focused on developing engineered cell and gene therapies for serious diseases. Its research centers on technologies designed to control the activity, timing and location of therapeutic proteins within engineered cells.

The company’s CytoDRiVE platform is intended to enable small-molecule regulation of protein expression, which may help improve the safety and effectiveness of cell therapies. Obsidian has applied this technology to immune-cell therapies, including programs designed to support the treatment of solid tumors, as well as to other therapeutic protein and gene-modulation applications.

Obsidian Therapeutics is based in the United States and has operated as a privately held biotechnology company, according to available company information.